Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic−mass spectrometry: applications to pharmacokinetics
-
Add time:08/27/2019 Source:sciencedirect.com
Nisoldipine, a second-generation dihydropyridine calcium antagonist, is a racemate compound used in the treatment of hypertension and coronary heart disease. This study presents an enantioselective HPLC-GC–MS method for the analysis of nisoldipine in human plasma and establishes confidence limits for its application to pharmacokinetic studies. Plasma samples were basified and extracted with toluene. The enantiomers were resolved on a Chiralcel® OD-H column using hexane–ethanol (97.5:2.5, v/v) and the (+)- and (−)-fractions were collected separately with the diode array detector switched off. For the quantification of the nisoldipine enantiomers a GC–MS with an Ultra 1 Hewlett-Packard column was used with the detector operated in the single-ion monitoring mode with electron-impact ionization (m/z 371.35 and 270.20 for nisoldipine and m/z 360.00 for the internal standard, nitrendipine). The method proved to be suitable for pharmacokinetic studies based on the low quantification limit (0.05 ng/ml for each enantiomer) and the broad linear range (0.05–50.0 ng/ml for each enantiomer). Low coefficients of variation (<15%) were demonstrated for both within-day and between-day assays. No interference from drugs associated with nisoldipine treatment was observed. The enantioselective pilot study on the kinetic disposition of nisoldipine administered in the racemic form to a hypertensive patient using a multiple dose regimen revealed the accumulation of the (+)-enantiomer with an AUC0–24 (+)/(−) ratio of approximately 8. Both enantiomers were quantified in plasma at a time interval of 24 h. This HPLC-GC–MS method is reliable, selective and sensitive enough to be used in clinical pharmacokinetic studies on the enantioselective disposition of nisoldipine in humans.
We also recommend Trading Suppliers and Manufacturers of M-NISOLDIPINE (cas 113578-26-0). Pls Click Website Link as below: cas 113578-26-0 suppliers
Prev:Validated LC–MS–MS method for determination of M-NISOLDIPINE (cas 113578-26-0) polymorphs in rat plasma and its application to pharmacokinetic studies
Next:Cyclic voltammetric behaviour of the O2/O2− redox couple at a HMDE and its interaction with nisoldipine) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Original ContributionsAntihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension08/29/2019
- Cyclic voltammetric behaviour of the O2/O2− redox couple at a HMDE and its interaction with nisoldipine08/28/2019
- Validated LC–MS–MS method for determination of M-NISOLDIPINE (cas 113578-26-0) polymorphs in rat plasma and its application to pharmacokinetic studies08/26/2019
- Molecular and Cellular PharmacologyThe inhibitory effects of M-NISOLDIPINE (cas 113578-26-0) on the 5-hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells via Ca2+ antagonism and antioxidant mechanisms08/25/2019
- Simultaneous determination of M-NISOLDIPINE (cas 113578-26-0) and its three metabolites in rat plasma by liquid chromatography–mass spectrometry08/24/2019
- Thermodynamic stability analysis of M-NISOLDIPINE (cas 113578-26-0) polymorphs08/23/2019
- Short communicationStudy of in vitro metabolism of M-NISOLDIPINE (cas 113578-26-0) in human liver microsomes and recombinant cytochrome P450 enzymes by liquid chromatography–mass spectrometry08/22/2019
- Short communicationStudies on separation and pharmacokinetics of M-NISOLDIPINE (cas 113578-26-0) enantiomers in beagle dog plasma by LC/MS/MS08/21/2019
- Original articleOn the dimorphism and the pressure–temperature state diagram of racemic M-NISOLDIPINE (cas 113578-26-0), a dihydropyridine calcium ion antagonistSur le dimorphisme et le diagramme d’état pression-température de la M-NISOLDIPINE (cas 113578-26-0) racémique, une dihydroyridine antagoniste08/20/2019